Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Hypogonadism in Men with Sickle Cell Disease (SCD): Benign Hematology Clinic, Detroit Medical Center, Detroit, MI

Abay Taddesse, MD, Indryas Woldie, MD, Panchali Khana, MD, Paul S. Swerdlow, MD, Jerry Chu, PhD, Judith Abrams, PhD, Abdul Abou-Samra, MD, PhD

Blood (2011) 118 (21): 2132.

https://doi.org/10.1182/blood.V118.21.2132.2132

Published: 2011

Journal Articles

Use of Plerixafor to Overcome Stem Cell Mobilization Failure: Long Term Follow up of Patients Proceeding to Transplant Using Plerixafor Mobilized Stem Cells

Abhinav Deol, MD, Judith Abrams, PhD, Ashiq Masood, MD, Zaid Al-Kadhimi, MD, Muneer H. Abidi, MD, Lois Ayash, MD, Voravit Ratanatharathorn, MD, Lawrence G Lum, MD, DSc, Joseph P. Uberti, MD, PhD

Blood (2011) 118 (21): 4390.

https://doi.org/10.1182/blood.V118.21.4390.4390

Published: 2011

Journal Articles

Cytoprotective Palifermin Allowed Melphalan Dose Escalation to 280mg/ 2 for Multiple Myeloma Patients with Normal Renal Function Receiving Autologous Stem Cell Transplantation (ASCT) - Final Results of a Phase 1 Trial

Muneer H. Abidi, MD, Nishant Tageja, MD, Lawrence G. Lum, MD, DSC, Judith Abrams, Zaid Al-Kadhimi, Lois Ayash, Simon Cronin, Pharm, D, Marie Ventimiglia, Abhinav Deol, MBBS, MD, Voravit Ratanatharathorn, MD, Joseph P. Uberti, MD, PhD

Blood (2010) 116 (21): 2401.

https://doi.org/10.1182/blood.V116.21.2401.2401

Published: 2010

Journal Articles

A Phase I Study of Bortezomib During Maintenance Phase After High-Dose Melphalan and Autologous Stem Cell Transplantation In Patients with Multiple Myeloma

Muneer H. Abidi, MD, Zartash Gul, MD, Lawrence G. Lum, MD, DSC, Judith Abrams, Simon Cronin, Pharm, D, Marie Ventimiglia, Abhinav Deol, MBBS, MD, Lois Ayash, Zaid Al-Kadhimi, Voravit Ratanatharathorn, MD, Joseph P. Uberti, MD, PhD

Blood (2010) 116 (21): 2387.

https://doi.org/10.1182/blood.V116.21.2387.2387

Published: 2010

Journal Articles

Melphalan and Dexamethasone Plus Bortezomib Induces Hematologic and Organ Responses in AL-Amyloidosis with Tolerable Neurotoxicity.

Jeffrey A Zonder, MD, Vaishali Sanchorawala, MD, Rachel M. Snyder, PhD, Jeffrey Matous, MD, Howard Terebelo, MD, Nalini Janakiraman, MD, Markus Y Mapara, MD, PhD, Silvana Lalo, MBA, Nishant Tageja, MD, Craig Webb, PhD, David Monsma, PhD, Catherine Sellers, RN, Judith Abrams, Statistician, Cristina Gasparetto, MD

Blood (2009) 114 (22): 746.

https://doi.org/10.1182/blood.V114.22.746.746

Published: 2009

Journal Articles

Peri-Engraftment Mucositis Amongst Patients Receiving Intravenous Busulfan/Fludarabine as Conditioning Regimen for Allogeneic Hemopoietic Stem Cell Transplantation.

Abhinav Deol, MD, Palaniappan Manickam, MD, Joseph Uberti, MD, PhD, Voravit Ratanatharathorn, MD, Lawrence G. Lum, MD, DSC, Lois Ayash, MD, Muneer H. Abidi, MD, Judith Abrams, PhD, Zaid Al-Kadhimi, MD

Blood (2009) 114 (22): 3346.

https://doi.org/10.1182/blood.V114.22.3346.3346

Published: 2009

Journal Articles

Influence of Prior Lenalidomide Exposure On Peripheral Blood Progenitor Cell Mobilization for Autologous Stem Cell Transplant in 144 Consecutive Patients with Multiple Myeloma.

Jason Valent, MD, Nishant Tageja, MD, Jeffrey A Zonder, MD, Richard Manasa, Judith Abrams, PhD, Tomoko Avila, Muneer H. Abidi, MD

Blood (2009) 114 (22): 3223.

https://doi.org/10.1182/blood.V114.22.3223.3223

Published: 2009

NARROW

Hypogonadism in Men with Sickle Cell Disease (SCD): Benign Hematology Clinic, Detroit Medical Center, Detroit, MI

Use of Plerixafor to Overcome Stem Cell Mobilization Failure: Long Term Follow up of Patients Proceeding to Transplant Using Plerixafor Mobilized Stem Cells

Cytoprotective Palifermin Allowed Melphalan Dose Escalation to 280mg/ 2 for Multiple Myeloma Patients with Normal Renal Function Receiving Autologous Stem Cell Transplantation (ASCT) - Final Results of a Phase 1 Trial

A Phase I Study of Bortezomib During Maintenance Phase After High-Dose Melphalan and Autologous Stem Cell Transplantation In Patients with Multiple Myeloma

Melphalan and Dexamethasone Plus Bortezomib Induces Hematologic and Organ Responses in AL-Amyloidosis with Tolerable Neurotoxicity.

Peri-Engraftment Mucositis Amongst Patients Receiving Intravenous Busulfan/Fludarabine as Conditioning Regimen for Allogeneic Hemopoietic Stem Cell Transplantation.

Influence of Prior Lenalidomide Exposure On Peripheral Blood Progenitor Cell Mobilization for Autologous Stem Cell Transplant in 144 Consecutive Patients with Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Hypogonadism in Men with Sickle Cell Disease (SCD): Benign Hematology Clinic, Detroit Medical Center, Detroit, MI

Use of Plerixafor to Overcome Stem Cell Mobilization Failure: Long Term Follow up of Patients Proceeding to Transplant Using Plerixafor Mobilized Stem Cells

Cytoprotective Palifermin Allowed Melphalan Dose Escalation to 280mg/ 2 for Multiple Myeloma Patients with Normal Renal Function Receiving Autologous Stem Cell Transplantation (ASCT) - Final Results of a Phase 1 Trial

A Phase I Study of Bortezomib During Maintenance Phase After High-Dose Melphalan and Autologous Stem Cell Transplantation In Patients with Multiple Myeloma

Melphalan and Dexamethasone Plus Bortezomib Induces Hematologic and Organ Responses in AL-Amyloidosis with Tolerable Neurotoxicity.

Peri-Engraftment Mucositis Amongst Patients Receiving Intravenous Busulfan/Fludarabine as Conditioning Regimen for Allogeneic Hemopoietic Stem Cell Transplantation.

Influence of Prior Lenalidomide Exposure On Peripheral Blood Progenitor Cell Mobilization for Autologous Stem Cell Transplant in 144 Consecutive Patients with Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only